Fluidigm Corporation (Nasdaq:FLDM) announced the use of its mass cytometry technology in a longitudinal study involving around 250 pediatric patients infected with SARS-CoV-2, the virus responsible for COVID-19. The study, called PRISM, aims to examine the immune response in children with varying COVID-19 symptoms, including multisystem inflammatory syndrome (MIS-C). Lead researchers emphasize the need for a deeper understanding of MIS-C to enhance patient management and treatment. Blood samples will be analyzed using Fluidigm's advanced technologies to glean insights into immune system activity.
Fluidigm Corporation (Nasdaq: FLDM) announced participation in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on February 18, 2021. Chris Linthwaite, President and CEO, will present updates on the company's business strategy and financial performance during a virtual fireside chat at 2:00 pm ET. A live webcast and replay will be available on the Fluidigm investor website. Fluidigm focuses on advancing health insights through its proprietary technologies across various research fields.
Fluidigm Corporation (Nasdaq: FLDM) has partnered with Helix Specialty Diagnostics and Genomic LTC DX to enhance COVID-19 testing using their Advanta™ Dx SARS-CoV-2 RT-PCR Assay. This collaboration aims to deliver 3,000 tests per day at CLIA certified labs in Missouri, employing saliva samples for non-invasive testing. The assay, which has received Emergency Use Authorization from the FDA, shows 100% agreement with nasopharyngeal swab results, thus providing an effective alternative. The partnership is positioned to support large-scale testing in educational institutions and long-term care facilities.
Fluidigm Corporation (Nasdaq:FLDM) has received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay, a saliva-based test for COVID-19 detection. The test offers a non-invasive collection method, demonstrating 100% agreement with nasopharyngeal samples in clinical studies. The European market for COVID-19 testing is projected to be worth $5-$7 billion in 2021. The Advanta Assay will be available for as low as 5 euros per test and targets private labs supporting testing for travel and workplace needs. Fluidigm continues to assess its assay's effectiveness against viral mutations.
Fluidigm Corporation (Nasdaq:FLDM) will report its fourth quarter and full year 2020 financial results on February 10, 2021, after market close. President and CEO Chris Linthwaite, along with CFO Vikram Jog, will lead a conference call at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results and operational progress. A press release with detailed financial information will be available prior to the call. Interested individuals can join the call via specified dial-in numbers or through a live webcast on the company's Investor Relations page.
Fluidigm Corporation (NASDAQ:FLDM) announced a new study validating the use of Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System. Conducted by Georgetown Lombardi Comprehensive Cancer Center, the study explores pancreatic cancer interactions with the immune system, identifying CDH11 as a potential therapeutic target. Key findings include significantly higher CDH11 levels in cancer-associated fibroblasts, enhanced immune activity in mice with reduced CDH11, and improved survival in CDH11-inhibited models. The study underscores the importance of IMC in protein and RNA detection for cancer research.
Fluidigm Corporation (Nasdaq:FLDM) announced the appointment of Dr. Ana K. Stankovic to its Board of Directors. Dr. Stankovic brings over 30 years of diverse experience in research and development across various sectors, including diagnostics. Currently a managing partner at Koliada Consulting, she previously served as Senior Vice President at Becton, Dickinson and Company, and held significant roles at Vanderbilt University and the CDC. This appointment aims to strengthen Fluidigm's strategy in diagnostics and public health, particularly in response to COVID-19.
Fluidigm Corporation (Nasdaq: FLDM) announced that its Advanta Dx SARS-CoV-2 RT-PCR Assay has received licensing from India's Central Drugs Standard Control Organisation for importation and sale. This saliva-based test is one of the first licensed in India, enabling noninvasive COVID-19 testing through designated labs. The license was granted to Premas Life Sciences, who will facilitate distribution. Fluidigm aims to expand testing capabilities as India faces a potential second wave of infections. The assay demonstrated 100% agreement with nasopharyngeal samples, enhancing its reliability.
Fluidigm Corporation (Nasdaq:FLDM) announces participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1-2, 2020. A pre-recorded fireside chat with President and CEO Chris Linthwaite will be available on November 24 at 10:00 am ET, discussing the company's business strategy and financial performance. The recording will be accessible on their investor website. Fluidigm specializes in translational and clinical research, focusing on cancer and immunology, providing multi-omic solutions to improve health insights.
Fluidigm Corporation (Nasdaq:FLDM) announced that researchers at Weill Cornell Medicine identified a unique phenotype of immune cell activity related to COVID-19, distinct from other lung infections. Utilizing the Fluidigm Hyperion Imaging System, the study revealed key findings such as reduced alveolar lacunar space and increased immune cell infiltration in COVID-19 patients. The study emphasizes the importance of understanding lung pathology to drive treatment approaches. Although results are not peer-reviewed yet, they suggest potential early intervention strategies to improve patient outcomes.